Industrial-Scale Production of High-Purity Antihemophilic Factor IX from Human Plasma
![]() |
Kang, Yong
(Central Research Center, Green Cross Corp.)
Choi, Yong-Woon (Central Research Center, Green Cross Corp.) Sung, Hark-Mo (Central Research Center, Green Cross Corp.) Sohn, Ki-Whan (Central Research Center, Green Cross Corp.) Shin, Jeong-Sup (Central Research Center, Green Cross Corp.) Kim, In-Seop (Department of Biological Sciences, College of Life Science and Nanotechnology, Hannam University) |
1 | O'Connell, N. M. (2003), Factor XI deficiency-from molecular genetics to clinical management, Blood Coagul. Fibrinolysis 14(Suppl 1), 59-64 DOI |
2 | Lusher, J. M. (1991), Tnrombogenicity associated with factor IX complex concentrates, Semin. Hematol. 28(suppl 6), 3-5 |
3 | Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004), Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma, Biotechnol. Bioprocess Eng. 9, 57-60 |
4 | Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000), Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VllI concentrate, J. Microbiol. 38, 187-191 |
5 | Valentino, L. A. and V. M. Oza (2006), Blood safety and the choice of anti-hemophilic factor concentrate, Pedatr. Blood Cancer 47, 245-254 DOI ScienceOn |
6 | Schneider, B., M. Becker, H. H. Brackman, and A. M. Eis-Hubinger (2004), Contantination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2, Thromb. Haemost. 92, 838-845 |
7 | Grinde, B., K. Stene-Johansen, B. Sharma, T. Hoel, M. Jensenius, and K. Skaug (1997), Characterization of an epidemic of hepatitis A virus involving intravenous drug abusers-infection by needle sharing?, J. Med. Virol. 53, 69-75 DOI ScienceOn |
8 | Hoots, W. K. (2001), Safety issues affecting hemophilia products, Transfus. Med. Rev. 15(Suppl 1), 11-19 DOI ScienceOn |
9 | Berkman, S. A. (1988), Infectious complications of blood transfusion, Blood Rev. 2, 206-210 DOI ScienceOn |
10 | Horowitz, M. S., C. Rooks, B. Horowitz, and M. W. Hilgartner (1986), Virus safety of solvent/detergent treated antihaemophiliac factor concentrates, Lancet 2, 186-189 |
11 | Klein, H. G. (2005), Pathogen inactivation technology: cleansing the blood supply, J. Intern. Med. 257, 224-237 DOI ScienceOn |
12 | Mosley, J. W. and J. Rakela (1999), Foundling viruses and transfusion medicine, Transfusion 39, 1041-1044 DOI ScienceOn |
13 | Kim, I. S., Y. W. Choi, and S. R. Lee (2004), Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine, J. Microbiol. Biotechnol. 14, 140-147 |
14 | Feldman, P. A., P. I. Bradbury, J. D. Williams, G. E. Sims, J. W. McPhee, M. A. Pinnell, L. Harris, G. I. Crombie, and D. R. Evans (1994), Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography, Blood Coagul. Fibrinolysis 5, 939-948 DOI |
15 | Yee, T. T. and C. A. Lee (2005), Transfusion-transmitted infection in hemophilia in developing countries, Semin. Thromb. Hemost. 31, 527-537 DOI ScienceOn |
16 | Tagariello G, P. G. Davoli, G. B. Gajo, E. De Biasi, R. Risato, R. Baggio, and A. Traldi (1999), Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion, Haemophilia. 5, 426-30 DOI ScienceOn |
17 | Oshima, K. H., T. T. Evans-strickfaden, A. K. Highsmith, and E. W. Ades (1996), The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins, Biologicals 24, 137-145 DOI ScienceOn |
18 | Kasper , C. L. (1975), Clinical use of prothromb in complex concentrate: Report on thrombiembolic complications, Thromb. Diath. Haemorrh. 33, 640-644 |
19 | Limentani, S. A., K. P. Gowell, and S. R. Deitcher (1995), High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential, Acta Haematol. 94(suppl 1), 12-17 DOI |
20 | Suomela, H. (1976), Human coagulation factor IX isolation and characterization, Eur. J. Biochem. 71, 145-154 DOI ScienceOn |
21 | World Federation of Hemophilia. (2004), Registry of clotting factor concentrates |
22 | Shin, J. S., Y. W. Choi, H. M. Sung, Y. -W. Ryu, and I. S. Kim (2006), Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment, Biotechnol. Bioprocess Eng. 11, 19-25 과학기술학회마을 DOI |
23 | Kohler, M., P. Hellstern, E. Lechler, P. Uberfuhr, and G. Muller-Berghaus (1998), Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates, Thrombo. Haemost. 80, 399-402 DOI |
24 | Lambert, T., M. Recht, L. A. Valentino, J. S. Powell, C. Udata, S. T. Sullivan, and D. A. Roth (2007), Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B, Haemophilia. 13, 233-243 DOI ScienceOn |
25 | Roberts, P. (1996), Virus safety of plasma products, Rev. Med. Virol. 6, 25-38 DOI ScienceOn |
26 | Bradford, M. M. (1976), A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248-254 DOI ScienceOn |
27 | Burnouf, T. and M. Radosevich (2003), Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia. 9, 24-37 DOI ScienceOn |
28 | Kim, J. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002), Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7, 340-346 DOI ScienceOn |
![]() |